Covalon Announces Third Quarter Fiscal 2022 Results
Covalon Technologies Ltd. reported a significant 25% drop in Q3 revenue to $4.5 million and a net loss of $1.6 million, compared to a profit of $0.7 million in Q3 2021. Despite a 10% rise in U.S. product revenue over nine months, total revenue was consistent at $12.8 million year-to-date. Operating expenses increased by $1.3 million as the company invests in sales and marketing. The company remains financially strong with no debt, and has initiated a share buyback program to enhance shareholder value.
- Strong balance sheet with no debt and significant cash reserves.
- 10% growth in U.S. product revenue over the last nine months.
- Expansion efforts in sales, marketing, and operations are underway.
- 25% decrease in Q3 revenue compared to the previous year.
- Net loss of $1.6 million for Q3 compared to net income of $0.7 million in Q3 2021.
- Operating expenses increased by $1.3 million, mainly due to increased headcount.
MISSISSAUGA, ON, Aug. 29, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2022 results.
Brian Pedlar, Covalon's President and CEO, said, "Covalon is making real and significant progress in transforming our sales, marketing, and operations teams to position us to achieve growth over the next few years. We are currently in active discussion regarding new business opportunities, while bringing on experienced and talented new executives that allow us to expand our United States hospital customer base. Given the adoption of Covalon's products, such as VALGuard®, IV Clear® and SurgiClear®, in four of the top five pediatric hospitals and over 50 major teaching hospitals in the United States to date, we are positioned to become standard of care in helping doctors and clinicians prevent blood stream and surgical site infections in these hospitals.
"The investments we are making today have yet to impact our top line, as revenue from continuing operations for the nine months ended June 30, 2022, was
"Covalon is in the fortunate financial position of having a strong balance sheet with significant cash, no debt, and a loyal customer base. Our management team is laser-focused on building Covalon into the healthcare powerhouse we are destined to be, given our unique life-saving medical technologies and relationships with major prestigious hospitals and large multinational medical companies we are actively working with today.
"I'm very encouraged with the growth prospects we are seeing today and our growing base of customers and clinicians that are using our products on a daily basis. We are a much stronger company today than a year ago. We strengthened our balance sheet and improved our operations since last year at this time. We also have a stronger, more talented leadership team. These improvements are already positively impacting our growth prospects and I am looking forward to seeing their impact on our financial performance in 2023 and 2024," continued Mr. Pedlar.
As previously announced, Covalon's Board of Directors decided to use our strong cash position to further strengthen the Company by buying back up to
A conference call and webcast to discuss Covalon's Q3 fiscal 2022 financial results will be held Monday, August 29th, 2022, at 9:00am EST. To view, listen to, and participate in the live webcast, please follow the link below:
https://app.webinar.net/nwjXzxokLQl
To listen and participate via the conference call, please dial:
North American Toll-Free: 1-888-664-6392
Local (Toronto): 416-764-8659
Confirmation Number: 97297097
Participants will be able to ask questions of Company management during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast.
A recording of the call will be available by calling 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 297097# until September 12th, 2022. A recording of the call will also be available on www.covalon.com under News & Events on the Investors tab.
Revenue for the three months ended June 30th, 2022 decreased
Product revenue for the nine-month period ended June 30, 2022 was consistent at
Development and consulting services revenue for the three-month period ended June 30th, 2022 increased by
Gross margin decreased to
Adjusted gross margin(1), for the nine-month period ended June 30, 2022, increased to
Operating expenses for the three months ended June 30, 2022 increased
Adjusted EBITDA(1) for Q3 fiscal 2022 was a loss of
(1) | See "Non-IFRS Measures" below, including for a reconciliation of the non-IFRS measures used in this release to the most comparable IFRS measures. |
The following unaudited table presents Covalon's consolidated statements of operations for the three- and nine-month periods ended June 30th, 2022 and 2021.
Three months ended June 30, | Nine months ended June 30, | ||||||
2022 | 2021 | 2022 | 2021 | ||||
Revenue | |||||||
Product | |||||||
Development and consulting services | 364,733 | 312,102 | 986,424 | 1,168,997 | |||
Licensing and royalty fees | 35,623 | 48,268 | 170,621 | 158,614 | |||
Total revenue | 4,526,006 | 6,034,374 | 12,756,185 | 12,950,721 | |||
Cost of sales | 2,378,276 | 2,786,874 | 6,574,017 | 6,319,487 | |||
Gross profit before operating expenses | 2,147,730 | 3,247,500 | 6,182,168 | 6,631,234 | |||
Operating expenses | |||||||
Operations | 586,071 | 231,772 | 1,472,250 | 806,158 | |||
Research and development activities | 288,882 | 295,716 | 846,530 | 840,892 | |||
Sales, marketing and agency fees | 1,580,128 | 555,536 | 4,316,515 | 1,621,888 | |||
General and administrative | 1,269,873 | 1,343,662 | 4,643,373 | 3,667,101 | |||
3,724,954 | 2,426,686 | 11,278,668 | 6,936,039 | ||||
Finance expenses | 31,376 | 105,769 | 81,617 | 301,475 | |||
Net income (loss) from continuing operations | (1,608,600) | 715,045 | (5,178,117) | (606,280) | |||
Net income (loss) from discontinued operations | - | 342,886 | (409,295) | 1,713,592 | |||
Net income (loss) | |||||||
Other comprehensive income (loss) Amount that may be reclassified to profit or loss | |||||||
Foreign currency translation adjustment - | 995,098 | (169,487) | 631,546 | (884,706) | |||
Foreign currency translation adjustment - | - | (72,940) | - | (422,959) | |||
Total comprehensive income (loss) | |||||||
(Loss) per common share of continuing operations | |||||||
Basic earnings (loss) per share (Note 12) | |||||||
Diluted earnings (loss) per share (Note 12) | |||||||
Income (loss) per common share of discontinued operations | |||||||
Basic earnings (loss) per share (Note 12) | |||||||
Diluted earnings (loss) per share (Note 12) | |||||||
Income (loss) per common share | |||||||
Basic earnings (loss) per share (Note 12) | |||||||
Diluted earnings (loss) per share (Note 12) | |||||||
This press release makes reference to certain non-IFRS measures. These measures are not recognized or defined measures under IFRS, do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS. The non-IFRS financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS. We use non-IFRS measures including "Adjusted Gross Margin" and "Adjusted EBITDA" to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS measures. We believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The following non-IFRS financial measures are presented in this news release, and a description of the calculation for each measure is included below:
- Adjusted Gross Margin is defined as gross profit before operating expenses, plus depreciation and amortization included in cost of sales, plus inventory provision amounts.
- Adjusted EBITDA is defined as net loss, plus interest expense, plus depreciation and amortization, plus stock-based compensation, less government subsidies, plus inventory provisions, plus accounts receivable write-off expenses.
You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to some of the adjustments in these non-IFRS financial measures. Because these non-IFRS financial measures may be defined differently by other companies in our industry, our definitions of these non-IFRS financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing their utility.
The table below provides a reconciliation of gross profit before operating expenses under IFRS in the consolidated financial statements to Adjusted Gross Margin for the three and nine months ended June 30th, 2022 and 2021. Management believes that Adjusted Gross Margin is useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months ended | Nine months ended June 30th, | ||||
2022 | 2021 | 2022 | 2021 | ||
Gross profit before operating | |||||
Add: Depreciation and amortization | 55,949 | 73,043 | 151,774 | 233,373 | |
Add: Inventory provisions | 216,803 | 123,598 | 1,009,772 | 129,938 | |
Adjusted Gross Margin | 2,420,482 | 3,444,141 | 7,343,714 | 6,994,545 | |
Adjusted Gross Margin (%) | 53 % | 57 % | 58 % | 54 % |
The table below provides a reconciliation of net loss under IFRS in the consolidated financial statements to Adjusted EBITDA for the three and nine months ended June 30th, 2022 and 2021. Management believes that these non-IFRS measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to funds its cash requirements from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months ended | Nine months ended June 30, | ||||
2022 | 2021 | 2022 | 2021 | ||
Net income (loss) | ( | ( | |||
Add: Interest expense | 31,376 | 105,769 | 81,617 | 301,475 | |
Add: Depreciation and amortization | 171,450 | 227,478 | 488,063 | 660,282 | |
Add: Share based compensation | 87,737 | (16,537) | 126,988 | 147,024 | |
Less: Government subsidies | - | (282,400) | - | (793,152) | |
Add: Inventory provisions | 216,803 | 123,598 | 1,009,772 | 715,343 | |
Adjusted EBITDA |
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results, the impact and timing of COVID-19 on operating activities and market conditions, and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/covalon-announces-third-quarter-fiscal-2022-results-301613459.html
SOURCE Covalon Technologies Ltd.
FAQ
What were Covalon's Q3 fiscal 2022 earnings results?
How is Covalon's revenue trending in fiscal 2022?
What is Covalon's strategy moving forward?